A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of SHR-1707 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
Latest Information Update: 13 Jan 2025
At a glance
- Drugs SHR-1707 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Atridia
Most Recent Events
- 10 Jan 2025 Status changed from recruiting to active, no longer recruiting.
- 20 May 2024 Status changed from not yet recruiting to recruiting.
- 14 Apr 2024 Planned initiation date changed from 15 Mar 2024 to 17 Apr 2024.